X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Under the terms of the agreement, CSL Seqirus will deliver an H5N8 A/Astrakhan virus vaccine candidate and will then sponsor a subsequent Phase 2 clinical trial to evaluate the candidate along with CSL Seqirus' proprietary adjuvant MF59®.
Lead Product(s): H5N8 A/Astrakhan Virus Vaccine,Squalene API
Therapeutic Area: Infections and Infectious Diseases Product Name: H5N8 A/Astrakhan
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: BARDA
Deal Size: $30.1 million Upfront Cash: Undisclosed
Deal Type: Agreement October 06, 2022
Details:
CSL said it will provide technical expertise and a donation of MF59 to the University of Queensland’s preclinical development program.
Lead Product(s): Squalene API
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: University of Queensland
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 12, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
